Abstract
The last decade has witnessed significant advances in the field of nuclear medicine therapy in Brazil with the approval of Lu-177 (for neuroendocrine tumors), Y-90 (for radioembolization) and recently Ra-223 (for bone metastases of prostate cancer). However, there is a great need for additional therapeutic options for patients with metastatic soft tissue prostate cancer. Based on the high…